LAURA
BASTERRETXEA BADIOLA
Publicaciones (25) Publicaciones de LAURA BASTERRETXEA BADIOLA
2024
-
Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients
International Journal of Molecular Sciences, Vol. 25, Núm. 13
2023
-
Zahartzea, ikerketa medikoen ikuspegitik
Elhuyar: zientzia eta teknika, Núm. 352, pp. 28-33
2022
2021
-
Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer
Journal of Clinical Medicine, Vol. 10, Núm. 8
-
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Nature Communications, Vol. 12, Núm. 1
-
Prediction of unplanned hospitalizations in older patients treated with chemotherapy
Cancers, Vol. 13, Núm. 6, pp. 1-11
-
Predictive factors for simultaneous distant metastasis in head and neck cancer patients during the diagnostic work-up
European Archives of Oto-Rhino-Laryngology, Vol. 278, Núm. 11, pp. 4483-4489
-
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
Frontiers in Oncology, Vol. 11
-
Undertreatment and overtreatment in older patients treated with chemotherapy
Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 381-387
2020
-
Online farmazia-arreta onkologiaren arloan: eredu pilotu berriak garatzen
Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 1, pp. 29-38
-
Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study
Oncologist, Vol. 25, Núm. 10, pp. e1516-e1524
2019
-
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 64-74
-
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789
2018
-
Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma
Critical Reviews in Oncology/Hematology, Vol. 121, pp. 45-50
2017
-
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)
European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
2016
-
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
BMC Cancer, Vol. 16, Núm. 1
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study
Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711
2006
-
Gastrointestinal stromal tumors presenting as pelvic masses
Gastroenterologia y Hepatologia, Vol. 29, Núm. 8, pp. 447-450